



POLICY TITLE	Intravitreal anti-VEGF/Biologic Injections		
CATEGORY	Medical Surgical	POLICY ID NUMBER	300_NYS
AUTHOR DATE	01/01/2023	LAST REVIEW DATE	
EXCLUSIONS	Applicable to Government Programs in New York State only.		

DISCLAIMER CPT® Codes, Descriptors, and other data are copyright 2023 American Medical Association (or such other date of publication of CPT®). All Rights Reserved to AMA. Additional resources include CMS Medicare Provider Guidelines @ CMS.gov. This information may not be sold, licensed, or unlawfully used and is intellectual property of EyeMed and the aforementioned entities.

Applicable Codes:

J0178 EYLEA (aflibercept) injection- intravitreal injection
Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration.

J0179 BEOVU (brolucizumab-dbl) injection-intravitreal injection
Brolucizumab-dbl is a human vascular endothelial growth factor (VEGF) inhibitor used as an intravitreal injection.

J2778 LUCENTIS (ranibizumab) injection-intravitreal injection
Ranibizumab, a recombinant humanized immunoglobulin G, kappa monoclonal antibody fragment, is a vascular endothelial growth factor A (VEGF-A) antagonist used as an intravitreal injection.

Indication and Limitations¹

Eylea

Treatment indications with approved dosage schedule - (supporting ICD-10 pages 3-7):

- Neovascular (Wet) age-related macular degeneration (AMD)
- Diabetic macular edema (DME)
- Macular edema associated with retinal vein occlusion.

¹ Physician attests at time of request submission that physician signed documentation across the full timeframe of treatment rendered (chart, procedures, order, testing interpretation) supports all indications and limitations for service based on this policy and industry billing guidance.

- 2 milligrams administered by intravitreal injection once every 4 weeks (monthly) for the first 12 weeks (3 months), THEN 2 milligrams administered by intravitreal injection once every 8 weeks [2 months]
- Although EYLEA (aflibercept) may be dosed as frequently as 2 milligrams every 4 weeks (monthly), additional efficacy was not demonstrated when EYLEA (aflibercept) was dosed every 4 weeks as compared to every 8 weeks.
- Max injections per calendar year = 16

Beovu

Treatment indications with approved dosage schedule (supporting ICD-10 pages 7 & 8):

- Neovascular (Wet) Age-Related Macular Degeneration (AMD)
 - 6 milligrams (0.05 mL of 120 mg/mL solution) monthly (approximately every 25-31 days) for the first three doses, followed by one dose of 6 milligrams (0.05 mL) every 8-12 weeks
 - Max injections per calendar year = 16
- Diabetic Macular Edema (DME)
 - 6 milligrams (0.05 mL of 120 mg/mL solution) every six weeks (approximately every 39-45 days) for the first five doses, followed by one dose of 6 milligrams (0.05 mL of 120 mg/mL solution) every 8-12 weeks
 - Max injections per calendar year = 16

Lucentis

Treatment indication with approved dosage schedule (supporting ICD-10 pages 8-12):

- Neovascular (Wet) Age-Related Macular Degeneration (AMD)
 - 0.5 milligrams (0.05 mL) is recommended to be administered by intravitreal injection once a month (approximately 28 days).
 - Although not as effective, patients may be treated with 3 monthly doses followed by less frequent dosing with regular assessment.
 - Although not as effective, patients may also be treated with one dose every 3 months after 4 monthly doses. Patients should be assessed regularly.
 - Max injections per calendar year = 26
- Macular Edema Following Retinal Vein Occlusion (RVO)
 - 0.5 milligrams (0.05 mL) is recommended to be administered by intravitreal injection once a month (approximately 28 days).
 - Max injections per calendar year = 26
- Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)
 - 0.3 milligrams (0.05 mL) is recommended to be administered by intravitreal injection once a month (approximately 28 days)
 - Max injections per calendar year = 26

- Myopic Choroidal Neovascularization (mCNV)
 - 0.5 mg (0.05 mL) is recommended to be initially administered by intravitreal injection once a month (approximately 28 days) for up to three months. Patients may be retreated if needed
 - Max injections per calendar year = 8

Additional Guidance – All Codes

- Ocular Coherence Tomography (OCT) and/or fluorescein angiography (FA) test results must be interpreted and firmly establish/support diagnosis
- Procedure note must include:
 - Actual administered drug, dosage, injection site, & route of administration
 - Injection lot # & expiration date
 - Post-injection vision check \geq CF
- Specific notation patient has been queried/screened for contraindicating/ co-morbidities.
- Avastin trial failure must clearly be indicated in chart:
 - Minimum 2-month treatment trial
 - Fewer than 3 lines of improvement on visual acuity testing
 - Medical necessity to change therapy from Avastin to one of the above-listed drugs.
- Informed consent stating all pertinent risks must include:
 - Date, consent to perform/waive, patient or representative signature, surgeon/physician signature, and witness signature
- Authorizations will be given for the time period of 12 months and will cover up to the listed maximum of injections during that time period. Additional injections requested will be subject to review and determinations will be made on a case-by-case basis and subject to medical necessity.
- It is expected that these services would be performed as indicated by current medical literature and/ or standards of practice. When services are performed in excess of established parameters, they may be subject to review for medical necessity.
- Before injections (other than Avastin) will be considered, there must be documentation showing that the member was put on Avastin trial for a minimum of two months and showed fewer than three lines of improvement in visual acuity.
- Clinical documentation must clearly support the necessity to change therapy and for the use of a different drug in place of Avastin.

Supporting Diagnoses

EYLEA (afibercept) injection- intravitreal injection

E08.311	Diabetes Mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema
E08.319	Diabetes Mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema

EYLEA (afibercept) injection- intravitreal injection

E08.3211-E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema,
E08.3291- E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema,
E08.3311- E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema,
E08.3391- E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema,
E08.3411- E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema,
E08.3491- E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema,
E08.3591- E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema,
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema
E09.3211-E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E09.3291-E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral
E09.3311-E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E09.3391-E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema,
E09.3411-E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema,
E09.3491-E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema
E09.3511-E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema
E09.3521-E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula
E09.3531-E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula
E09.3541-E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment
E09.3551-E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy
E09.3591-E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema

EYLEA (afibercept) injection- intravitreal injection

E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema
E10.3211-E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E10.3291-E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema
E10.3311-E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E10.3391-E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema
E10.3411-E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema
E10.3491-E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema
E10.35.11-E10.35.13	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema
E10.35.21-E10.35.23	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula
E10.35.31-E10.35.33	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula
E10.35.41-E10.35.43	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment
E10.35.51-E10.35.53	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy
E10.35.91-E10.35.93	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy without macular edema
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema
E11.3211-E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E11.3291-E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema
E11.3311-E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E11.3391-E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema
E11.3411-E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema
E11.3491-E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema
E11.3511-E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema
E11.3521-E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula

EYLEA (afibercept) injection- intravitreal injection

E11.3531-E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula,
E11.3541-E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment
E11.3551-E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy
E11.3591-E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema
E13.3211- E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E13.3291- E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema
E13.3311- E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E13.3391- E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema
E13.3411- E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema
E13.3491- E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema
E13.3511- E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema
E13.3521- E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula,
E13.3531- E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula
E13.3541- E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment
E13.3551- E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy
E13.3591- E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema
H34.8110	Central retinal vein occlusion, right eye, with macular edema
H34.8111	Central retinal vein occlusion, right eye, with retinal neovascularization
H34.8112	Central retinal vein occlusion, right eye, stable
H34.8120	Central retinal vein occlusion, left eye, with macular edema
H34.8121	Central retinal vein occlusion, left eye, with retinal neovascularization
H34.8122	Central retinal vein occlusion, left eye, stable
H34.8130	Central retinal vein occlusion, bilateral, with macular edema
H34.8131	Central retinal vein occlusion, bilateral, with retinal neovascularization
H34.8132	Central retinal vein occlusion, bilateral, stable

EYLEA (afibercept) injection- intravitreal injection

H34.8310	Tributary (branch) retinal vein occlusion, right eye, with macular edema
H34.8311	Tributary (branch) retinal vein occlusion, right eye, with retinal neovascularization
H34.8312	Tributary (branch) retinal vein occlusion, right eye, stable
H34.8320	Tributary (branch) retinal vein occlusion, left eye, with macular edema
H34.8321	Tributary (branch) retinal vein occlusion, left eye, with retinal neovascularization
H34.8322	Tributary (branch) retinal vein occlusion, left eye, stable
H34.8330	Tributary (branch) retinal vein occlusion, bilateral, with macular edema
H34.8331	Tributary (branch) retinal vein occlusion, bilateral, with retinal neovascularization
H34.8332	Tributary (branch) retinal vein occlusion, bilateral, stable
H35.3210	Exudative age-related macular degeneration, right eye, stage unspecified
H35.3211	Exudative age-related macular degeneration, right eye, with active choroidal neovascularization
H35.3212	Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization
H35.3213	Exudative age-related macular degeneration, right eye, with inactive scar
H35.3220	Exudative age-related macular degeneration, left eye, stage unspecified
H35.3221	Exudative age-related macular degeneration, left eye, with active choroidal neovascularization
H35.3222	Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization
H35.3223	Exudative age-related macular degeneration, left eye, with inactive scar
H35.3230	Exudative age-related macular degeneration, bilateral, stage unspecified
H35.3231	Exudative age-related macular degeneration, bilateral, with active choroidal neovascularization
H35.3232	Exudative age-related macular degeneration, bilateral, with inactive choroidal neovascularization
H35.3233	Exudative age-related macular degeneration, bilateral, with inactive scar
H35.351-H35.353	Cystoid macular degeneration
H35.81	Retinal edema

BEOVU (brolucizumab-dbil)) injection-intravitreal injection

H35.3210	Exudative age-related macular degeneration, right eye, stage unspecified
H35.3211	Exudative age-related macular degeneration, right eye, with active choroidal neovascularization
H35.3212	Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization
H35.3213	Exudative age-related macular degeneration, right eye, with inactive scar
H35.3220	Exudative age-related macular degeneration, left eye, stage unspecified
H35.3221	Exudative age-related macular degeneration, left eye, with active choroidal neovascularization
H35.3222	Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization
H35.3223	Exudative age-related macular degeneration, left eye, with inactive scar
H35.3230	Exudative age-related macular degeneration, bilateral, stage unspecified

BEOVU (brolucizumab-dbl)) injection-intravitreal injection

H35.3231	Exudative age-related macular degeneration, bilateral, with active choroidal neovascularization
H35.3232	Exudative age-related macular degeneration, bilateral, with inactive choroidal neovascularization
H35.3233	Exudative age-related macular degeneration, bilateral, with inactive scar

LUCENTIS (ranibizumab) injection-intravitreal injection

E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema
E08.3211- E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema
E08.3291- E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema
E08.3311- E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema
E08.3391- E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral
E08.3411- E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3491- E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema
E08.3511- E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema
E08.3521- E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula,
E08.3531- E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula
E08.3541- E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment,
E08.3551- E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy
E08.3591- E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema
E09.3211-E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye

LUCENTIS (ranibizumab) injection-intravitreal injection

E09.3291- E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye
E09.3311- E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E09.3391- E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema
E09.3411- E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema,
E09.3491- E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema
E09.3511- E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema
E09.3521- E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula
E09.3531- E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula
E09.3541- E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment,
E09.3551- E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy
E09.3591- E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema
E10.3211-E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E10.3291-E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema
E10.3311-E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E10.3391-E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema
E10.3411-E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema
E10.3491-E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema
E10.3511-E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema
E10.3521-E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula

LUCENTIS (ranibizumab) injection-intravitreal injection

E10.3531-E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula,
E10.3541-E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment
E10.3551-E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy
E10.3591-E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema
E11.3211- E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E11.3291- E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema
E11.3311-E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E11.3391- E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema
E11.3411- E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema
E11.3491- E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema
E11.3511-E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema
E11.3521- E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula
E11.3531- E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula
E11.3541- E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment
E11.3551- E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy
E11.3591- E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema
E13.3211- E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E13.3291- E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema
E13.3311- E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema

LUCENTIS (ranibizumab) injection-intravitreal injection

E13.3391-E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema
E13.3411- E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema
E13.3491- E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema
E13.3511- E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema
E13.3521- E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula
E13.3531- E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula
E13.3541- E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment
E13.3551- E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy
E13.3591- E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema
H34.8110	Central retinal vein occlusion, right eye, with macular edema
H34.8111	Central retinal vein occlusion, right eye, with retinal neovascularization
H34.8112	Central retinal vein occlusion, right eye, stable
H34.8120	Central retinal vein occlusion, left eye, with macular edema
H34.8121	Central retinal vein occlusion, left eye, with retinal neovascularization
H34.8122	Central retinal vein occlusion, left eye, stable
H34.8130	Central retinal vein occlusion, bilateral, with macular edema
H34.8131	Central retinal vein occlusion, bilateral, with retinal neovascularization
H34.8132	Central retinal vein occlusion, bilateral, stable
H34.8310	Tributary (branch) retinal vein occlusion, right eye, with macular edema
H34.8311	Tributary (branch) retinal vein occlusion, right eye, with retinal neovascularization
H34.8312	Tributary (branch) retinal vein occlusion, right eye, stable
H34.8320	Tributary (branch) retinal vein occlusion, left eye, with macular edema
H34.8321	Tributary (branch) retinal vein occlusion, left eye, with retinal neovascularization
H34.8322	Tributary (branch) retinal vein occlusion, left eye, stable
H34.8330	Tributary (branch) retinal vein occlusion, bilateral, with macular edema
H34.8331	Tributary (branch) retinal vein occlusion, bilateral, with retinal neovascularization
H34.8332	Tributary (branch) retinal vein occlusion, bilateral, stable
H35.051-H35.053	Retinal neovascularization, unspecified
H35.3210-H35.3213	Exudative age-related macular degeneration, right eye, (stage unspecified, with active choroidal neovascularization, with inactive scar)
H35.3220-H35.3223	Exudative age-related macular degeneration, left eye, (stage unspecified, with active choroidal neovascularization, with inactive scar)
H35.3230-H35.3233	Exudative age-related macular degeneration, bilateral, (stage unspecified, with active choroidal neovascularization, with inactive scar)
H35.351-H35.353	Cystoid macular degeneration

LUCENTIS (ranibizumab) injection-intravitreal injection

H35.81	Retinal edema
H44.2A1-H44.2A3	Degenerative myopia with choroidal neovascularization,

References

- Beovu (Brolucizumab). [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; December 2022.
- Eylea (Aflibercept). [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals Incorporated; February 2023. Accessed online July 25, 2023.
- CGS Administrators, LLC. Local Coverage Article. “(A52451) Billing and Coding: Ranibizumab and biosimilars, Aflibercept, Brolucizumab-dbl and Faricimab-svoa”. Revision date 04/01/23. Accessed online June 20,2023 at CMS.gov.
- Lucentis (Ranizumab). [prescribing information]. South San Francisco, CA: Genentech Incorporated; March 2018. Accessed online June 20,2023.

Review and Approval Change Log

- | | |
|-----------|--|
| July 2022 | Medical Surgical policy drafted |
| June 2023 | Scope limited to NYS medical surgical prior authorization requirement. |